Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WenyangJianpi-qushi Decoction + mometasone furoate is a combination therapy consisting of a traditional Chinese medicine (TCM) herbal decoction and the topical corticosteroid mometasone furoate. The decoction, self-made according to TCM principles, is designed to "warm yang," "strengthen the spleen," and "remove dampness”—concepts in TCM associated with improving immune function and reducing inflammation. Mometasone furoate is a synthetic glucocorticoid used topically for its anti-inflammatory, antipruritic, and vasoconstrictive effects. This combination has been studied for atopic dermatitis of the spleen deficiency and dampness accumulation type, showing improved clinical efficacy compared to corticosteroid alone by reducing SCORAD scores (a measure of disease severity), serum IgE levels, peripheral blood eosinophil counts, recurrence rates, and increasing total effective rate without significant safety concerns[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on WenyangJianpi-qushi Decoction + mometasone furoate.